You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK):旗下療法對Omicron BA.2亞型變異株保持中和活性
阿思達克 05-10 08:44
騰盛博藥-B(02137.HK)公布,新的研究數據表明公司的長效新冠中和抗體安巴韋單抗和羅米司韋單抗聯合療法,對新冠病毒變異病毒株Omicron BA.2亞型變異株保持中和活性。 在美國國立衛生研究院和美國國家過敏和傳染病研究所認證的美國馬里蘭大學實驗室進行的活病毒中和實驗數據表明,在給藥14天后,安巴韋單抗和羅米司韋單抗聯合療法的總血藥濃度仍保持中和超過90%的奧密克戎BA.2亞型變異株活病毒所需濃度的60倍。儘管相對於野生型新冠變異株,Omicron BA.2亞型變異株刺突蛋白中的突變導致了半抑制濃度的增加,公司的聯合療法仍然對其有足夠治療作用將至少持續兩周或更長時間。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account